Rapid-Antigen Test Negative Malaria in a Traveler Returning From Thailand, Molecularly Diagnosed as Plasmodium knowlesi

Maria S. Mackroth,1 Dennis Tappe,2 Egbert Tannich,2 Marylyn Addo,1 and Camilla Röthe1

1Ist Department of Medicine, Section of Tropical Medicine, University Medical Centre Hamburg-Eppendorf, and 2Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany

Plasmodium knowlesi has been identified in the last decade as a fifth species causing malaria in areas of South East Asia. Due to its short erythrocytic cycle, rapid development of high parasitemia and severe manifestations are frequently observed. Therefore, prompt diagnosis of infection is essential to prevent complications, but the low sensitivity of rapid diagnostic tests for P knowlesi pose a diagnostic challenge in acute settings. In this study, we report the case of a German traveler to Thailand, who was treated for P knowlesi malaria after returning to Germany. Rapid antigen test for malaria was negative on presentation. Diagnosis of a nonfalciparum malaria was made based on microscopy, and species definition was determined using polymerase chain reaction technique.

CASE PRESENTATION

In February 2015, a 42-year-old German male presented to the emergency department of the University Medical Centre in Hamburg, Germany with a 6-day history of fever up to 40°C, arthralgia, and retro-orbital pain. The day before presentation, he had returned from a 10-week trip to Thailand, where he had spent 2 months on Little Koh Chang, an island in the Andaman Sea in the Ranong Province. At the end of his trip, he spent 5 days in Hua Hin, a town at the Gulf of Thailand in the Prachuap Khiri Khan Province, and 5 days in Bangkok. He had not taken antimalarial chemoprophylaxis while being in Thailand.

There was no past medical history of note. On clinical examination, a temperature of 39.1°C, blood pressure of 156/80 mmHg, and a pulse of 106/minute were noted. The respiratory rate was recorded at 16 breaths/minute with an oxygen saturation of 95% on room air. The full blood count showed a thrombocytopenia of 81 × 10^9/L and was otherwise normal; the C-reactive protein was 55 mg/L (reference range up to 5 mg/L). The liver enzymes were slightly elevated with an aspartate aminotransferase of 106 U/L (reference range, 10–50 U/L) and an alanine aminotransferase of 62 U/L (reference range, 10–50 U/L). The bilirubin was 0.5 mg/dL (reference range, <1.2 mg/dL). Rapid diagnostic tests for malaria (Alere BinaxNOW, which detects the Plasmodium falciparum-specific Histidine-rich Protein II and the panmalarial Aldolase) and dengue fever gave negative results. However, a thick blood film showed plasmodia trophozoites at a density of 920/µL. On thin film, the microscopists on duty were unable to differentiate the Plasmodium species in the acute setting. Based on the negative result of the rapid-diagnostic test, a nonfalciparum malaria was suspected. The patient was admitted to the infectious disease ward. Treatment was started with atovaquone/proguanil 250/100 mg 4 tablets daily over 3 days. The patient rapidly recovered and was discharged 4 days after admission. For further parasite differentiation, malaria microscopy was repeated by the head parasitologist. After intense reading of the Giemsa-stained thin blood film, 2 parasite-infected erythrocytes were identified with morphological characteristics compatible with Plasmodium malariae or P knowlesi infection (Figure 1). Subsequently, species-specific polymerase chain reactions (PCRs) for the 5 human plasmodia species confirmed the presence of a monoinfection with P knowlesi [1, 2].

DISCUSSION

Plasmodium knowlesi was first described in detail in 1932 by Biraj Das Gupta and Robert Knowles in Kalkutta as malaria of macaques [3]. Plasmodium knowlesi gained recognition as the fifth human malaria parasite in 2004, when Singh et al [4] discovered that 58% of microscopically diagnosed malaria patients in the Kapit Division, Sarawak, Borneo, Malaysia were positive for P knowlesi by PCR.

So far, the vast majority of P knowlesi patients have been diagnosed in Sabah and Sarawak, Borneo, Malaysia. Increasing incidences of P knowlesi malaria have been reported from Sabah and Sarawak in the last few years [5–7]. Plasmodium knowlesi infections have also been identified in Thailand, Vietnam, Singapore, Indonesia, Cambodia, Myanmar, and the Philippines [8, 9]. Travelers returning from Southeast Asia with imported P knowlesi malaria have occasionally been reported from non endemic...
Forests are the natural habitat of the natural hosts of Plasmodium knowlesi, and vicinity to natural forest areas is the main risk factor for contracting P. knowlesi infection. Forests are the natural habitat of the natural hosts of P. knowlesi, the long- and pig-tailed macaques [14]. Most patients with documented P. knowlesi malaria lived in or at the fringe of forestry areas [3]. Although our patient had not specifically visited a forest or national park, he stayed close to forestry areas on Little Koh Chang and participated in a rafting tour close to Hua Hin as potential exposures. From both areas, the Ranong and Prachuap Khiri Khan provinces, P. knowlesi infections in humans have been repeatedly reported [13,15–18]. The short time duration between the rafting tour and development of fever (4 days) make an infection at Little Koh Chang more likely, but short incubation periods with a minimum of 3 days have been observed with P. knowlesi [19].

Plasmodium knowlesi presents several diagnostic challenges. Plasmodium knowlesi can be detected by rapid diagnostic tests targeting panmalarial Plasmodium lactate dehydrogenase (pLDH), Plasmodium vivax-specific pLDH, P. falciparum-specific pLDH, or panmalarial Aldolase, but sensitivities are low [14,20,21]. In particular, in infections with low parasitemia, rapid diagnostic tests often fail to diagnose an acute P. knowlesi malaria, as seen with our patient [20]. Therefore, diagnosis of infection relies primarily on microscopy of blood films, which requires highly trained microscopists. However, even in the hands of an experienced microscopist, P. knowlesi can be easily misdiagnosed as Plasmodium malariae due to morphological similarity of the 2 parasite species. Molecular genetic analysis of malaria patients in Sabah, Borneo determined that up to 83% of malaria patients microscopically diagnosed with P. malariae malaria were indeed infected with P. knowlesi [22]. Polymerase chain reaction is the most reliable method to distinguish P. knowlesi from other species, but it is usually not available in an acute setting. This diagnostic challenge has important consequences for patient management. Although P. malariae malaria rarely causes complications, being termed “benign quartan malaria”, P. knowlesi infection can potentially be fatal because the parasite is able to rapidly develop high parasitemia due to its short erythrocytic cycle of only 24 hours. Severe courses of P. knowlesi malaria are observed in approximately 10% of hospitalized patients and include respiratory distress syndrome or renal failure [6,23,24].

Several treatment options exist for uncomplicated P. knowlesi infection. To date, chloroquine remains widely used for the treatment of confirmed P. knowlesi infection [8,25]. However, due to the increasing chloroquine resistance rates among P. falciparum in Asia, chloroquine should only be used when a P. falciparum infection or coinfection can be safely excluded [8]. Alternatively, artemisinin-combination drugs are increasingly used as first choice and offer the advantage to cover all malaria species [8,26–28]. Furthermore, the first randomized controlled trial for the treatment of P. knowlesi malaria, which compared treatment with chloroquine to mefloquine-artesunate, showed a faster parasite clearance when using mefloquine-artesunate [29]. Other treatment options for P. knowlesi include atovaquone/proguanil, which also treats all malaria species [27]. Severe P. knowlesi infection should be treated with parenteral artesunate [8,28].

CONCLUSIONS

Our case highlights the need to consider P. knowlesi malaria in febrile patients residing in or traveling from Southeast Asia in whom rapid antigen test for malaria is negative and microscopic species definition of plasmodia is inconclusive or a nonfalciparum species is suspected. Polymerase chain reaction assays remain an important tool to reliably identify P. knowlesi.

Acknowledgments

Authors contributions. M. S. M. and C. R. treated the patient. D. T. and E. T. read the blood films and conducted the polymerase chain reaction analysis. All authors contributed to writing the report.
**Potential conflicts of interest.** All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

**References**

1. Link L, Bart A, Verhaar N, et al. Molecular detection of *Plasmodium knowlesi* in a Dutch traveler by real-time PCR. J Clin Microbiol 2012; 50:2523–4.
2. Shokoples SE, Diao M, Kowalewska-Grochowska K, Yanow SK. Multiplexed real-time PCR assay for discrimination of *Plasmodium* species with improved sensitivity for mixed infections. J Clin Microbiol 2009; 47:975–80.
3. Muller M, Schlangenhal P. *Plasmodium knowlesi* in travellers, update 2014. Int J Infect Dis 2014; 22:55–64.
4. Singh B, Kim Sung L, Matusop A, et al. A large focus of naturally acquired *Plasmodium knowlesi* infections in human beings. Lancet 2004; 363:1017–24.
5. William T, Jelip J, Menon J, et al. Changing epidemiology of malaria in Sabah, Malaysia: increasing incidence of *Plasmodium knowlesi*. Malar J 2014; 13:390.
6. Rajahram GS, Barber BE, William T, et al. Falling *Plasmodium knowlesi* malaria death rate among adults despite rising incidence, Sabah, Malaysia, 2010–2014. Emerg Infect Dis 2016; 22:41–8.
7. Sarawak State Health Department: Weekly Epid News. Available at: http://jksarawak.moh.gov.my/en/modules/wfdownloads/viewcat.php?start=5&cid=31. Accessed 8 February 2016.
8. World Health Organization: Informal Consultation on the Public Health Importance of *Plasmodium knowlesi*. Available at: http://www.wpro.who.int/mvp/documents/docs/Pknowlesi_final_report.pdf. Accessed 8 February 2016.
9. Cox-Singh J, Singh B. *Knowlesi* malaria: newly emergent and of public health importance? Trends Parasitol 2008; 24:406–10.
10. Knopf I, Seilmaier M, Berens-Riha N, et al. *Monkey malaria (Plasmodium knowlesi infection)* after travelling to Thailand, Dtch Med Wochenschr 2015; 140:815–7.
11. Ehrhardt J, Trein A, Kremsner P, Frank M. *Plasmodium knowlesi* and HIV co-infection in a German traveller to Thailand. Malar J 2013; 12:283.
12. Seilmaier M, Hartmann W, Beissner M, et al. Severe *Plasmodium knowlesi* infection with multi-organ failure imported to Germany from Thailand/Myanmar. Malar J 2014; 13:422.
13. Orth H, Jensen BO, Holtfreter MC, et al. *Plasmodium knowlesi* infection imported to Germany, January 2013. Euro Surveill 2013; 18 pii=20603.
14. Singh B, Daneshvar C. Human infections and detection of *Plasmodium knowlesi*. Clin Microbiol Rev 2013; 26:165–84.
15. Jongwutiwes S, Buppan P, Kosuvin R, et al. *Plasmodium knowlesi* malaria in humans and macaques, Thailand. Emerg Infect Dis 2011; 17:1799–806.
16. Jongwutiwes S, Putaporntip C, Iwasaki T, et al. Naturally acquired *Plasmodium knowlesi* malaria in human, Thailand. Emerg Infect Dis 2004; 10:2211–3.
17. Sermsvitayawong N, Singh B, Nishibuchi M, et al. Human *Plasmodium knowlesi* infection in Ranong province, southwestern border of Thailand. Malar J 2012; 11:36.
18. Putaporntip C, Hongririmuang T, Seerancharoen C, et al. Differential prevalence of *Plasmodium* infections and cryptic *Plasmodium knowlesi* malaria in humans in Thailand. J Infect Dis 2009; 199:1143–50.
19. Antinori S, Galimberti L, Milazzo L, Corbellino M. *Plasmodium knowlesi*: the emerging zoonotic malaria parasite. Acta Trop 2013; 125:191–201.
20. Grigg MJ, William T, Barber BE, et al. Combining parasite lactate dehydrogenase-based and histidine-rich protein 2-based rapid tests to improve specificity for diagnosis of malaria due to *Plasmodium knowlesi* and other *Plasmodium* species in Sabah, Malaysia. J Clin Microbiol 2014; 52:2053–60.
21. Barber BE, William T, Grigg MJ, et al. Evaluation of the sensitivity of a pLDH-based and an aldolase-based rapid diagnostic test for diagnosis of uncomplicated and severe malaria caused by PCR-confirmed *Plasmodium knowlesi*, *Plasmodium falciparum*, and *Plasmodium vivax*. J Clin Microbiol 2013; 51:1118–23.
22. Cox-Singh J, Davis TM, Lee KS, et al. *Plasmodium knowlesi* malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008; 46:165–71.
23. Daneshvar C, Davis TM, Cox-Singh J, et al. Clinical and laboratory features of human *Plasmodium knowlesi* infection. Clin Infect Dis 2009; 49:852–60.
24. Barber BE, William T, Grigg MJ, et al. A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from *Plasmodium knowlesi* and *Plasmodium vivax* but no mortality with early referral and artesunate therapy. Clin Infect Dis 2013; 56:383–97.
25. Vadiavelan M, Dutta T. Recent advances in the management of *Plasmodium knowlesi* infection. Trop Parasitol 2014; 4:31–4.
26. Visser BJ, Wieten RW, Kroon D, et al. Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malar J 2014; 13:463.
27. Askling HH, Brunsell F, Burchard G, et al. Management of imported malaria in Europe. Malar J 2012; 11:328.
28. Ministry of Health Malaysia: Management Guidelines of Malaria in Malaysia. Available at: http://www.moh.gov.my/english.php/pages/view/118. Accessed 8 February 2016.
29. Grigg MJ, William T, Menon J, et al. Artesunate-mefloquine versus chloroquine for treatment of uncomplicated *Plasmodium knowlesi* malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial. Lancet Infect Dis 2016; 16:180–8.